Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Yusahng Green Chemical was a biotechnology company based in Lubbock, Texas, that focused on developing natural product-based anticancer therapies. The company's primary research centered on NI-07 (NeoImmune-07), a water-soluble compound derived from the Greater Burdock plant (Arctium lappa). Preclinical studies conducted in collaboration with Texas Tech University and Seoul National University demonstrated that NI-07 possesses selective cytotoxic properties against various solid tumor cell lines, including breast, lung, and prostate cancers, while exhibiting minimal toxicity to normal cells. Although the compound showed promise in in vitro and in vivo mouse models, the company has not shown significant public activity since the early 2010s. The company's work was primarily academic in nature, involving researchers from both the United States and South Korea.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yusahng Green Chemical.